Articles By Jack Cush, MD
The RheumNow Week in Review – 21 April 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.com:
Read Article
Paradoxical Toxicities with TNF Inhibitors
Something is curiously wrong when a drug induces the disease it is intended to treat. Yet this phenomenon has been described with all five FDA-approved TNF inhibitors.
Read Article
Anti-IL-23 Therapy Effective in Crohn's Disease
Lancet has reported the results of risankizumab, an interleukin-23 (IL-23) inhibitor, in Crohn's disease. Risankizumab is a humanised monoclonal antibody targeting the p19 subunit of interleukin-23, and is being developed for Crohn's disease.
Read Article
The Cost of Not Taking Medicine
The NY Times points out "there is is an out-of-control epidemic in the United States that costs more and affects more people than any disease Americans currently worry about. It’s called nonadherence to prescribed medications, and it is — potentially, at least — 100 percent preventable by the very individuals it afflicts.
Read Article
FDA Delays Baricitinib Decision
Eli Lilly and Company and Incyte Corporation announced today that the U.S. Food and Drug Administration (FDA) has delayed its' decision on baricitinib by issuing a complete response letter for baricitinib's New Drug Application.
Read Article
The RheumNow Week in Review – 14 April 2017
Dr. Jack Cush reviews the past week's news, articles and advances from RheumNow.com.
Read Article
Acute Steroid Use Comes with Risk
Steroids are known for their acute therpeutic wonders and chronic hazards. Hence most practitioners are comfortable using short term, limited dose corticosteroids for a variety of ailments.
Read Article
Celecoxib Plus PPI Preferred in High Risk Patients
When do the risks outweigh the benefits of NSAIDs use, especially in those with prior cardiovascular and gastrointestinal events? The CONCERN study has tested the effects of proton-pump inhibitor (PPI) in preventing GI bleeds when using NSAIDs and ASA.
Read Article
Spinal Manipulation Equal to NSAIDS for Acute Low Back Pain
JAMA has published a review of 15 RCTs (1711 patients) analyzing the role of spinal manipulation therapy in patients with acute low back pain. The authors found modest improvements in pain and function at up to 6 weeks, with temporary minor musculoskeletal harms.
Read Article
Stroke Risk Highest in the First Year of Lupus
Arkema et al has published in Annals of Rheumatic Disease a study showing that ischaemic and haemorrhagic stroke (CVA) is elevated in systemic lupus erythematosus (SLE) compared with the general population, especially in the first year.
Read Article
